Residency · Residency · Geriatrics

Heart Failure in the Elderly

Introduction

Heart failure (HF) is among the most prevalent and consequential cardiovascular conditions in geriatric medicine, with prevalence increasing dramatically across the lifespan: approximately 2 percent at ages 40 to 59, 5 percent at ages 60 to 69, 10 percent at ages 70 to 79, and 15 to 20 percent in adults aged 80 and older. The median age at heart failure diagnosis is 77 years, and HF is the leading cause of hospitalization in adults aged 65 and older. Heart failure with preserved ejection fraction (HFpEF) predominates in the elderly population, accounting for more than 50 percent of cases in those aged 80 and older, with a particular predilection for women. Despite advances in modern therapies, the five-year mortality for heart failure remains approximately 50 percent, and one-year mortality following hospitalization is 25 to 30 percent. A critical limitation of the evidence base is that elderly HF patients are systematically underrepresented in clinical trials, where the mean age is typically 60 to 65 years, while the typical HF patient in clinical practice is 75 to 80 years old.

Pathophysiology in the Elderly

Age-Related Cardiac Changes Predisposing to HF

The aging cardiovascular system undergoes structural and functional changes that predispose to heart failure. Increased arterial stiffness leads to increased afterload, which in turn drives concentric left ventricular hypertrophy. Impaired diastolic relaxation results from changes in calcium handling within cardiomyocytes. Decreased beta-adrenergic responsiveness reduces chronotropic and inotropic reserve, limiting the heart's ability to augment cardiac output during physiological stress. Progressive myocardial fibrosis from increased collagen deposition reduces ventricular compliance. While resting cardiac output is generally preserved, the capacity to augment output under stress is significantly diminished.

An increasingly recognized entity is wild-type transthyretin amyloidosis (ATTRwt), in which misfolded transthyretin protein deposits in the myocardium, contributing to restrictive cardiomyopathy. Autopsy studies have demonstrated a prevalence of 13 to 25 percent in HFpEF patients aged 75 and older, making cardiac amyloidosis a far more common cause of heart failure in the elderly than previously appreciated.

HF Classification

Heart failure is classified by ejection fraction into three categories. HFrEF (ejection fraction 40 percent or below) reflects systolic dysfunction and is more common in men and in patients with coronary artery disease. HFmrEF (ejection fraction 41 to 49 percent) represents borderline dysfunction and may benefit from therapies used for HFrEF. HFpEF (ejection fraction 50 percent or above) reflects predominantly diastolic dysfunction and is more common in women, elderly patients, and those with hypertension, obesity, atrial fibrillation, and diabetes. HFpEF is increasingly understood as a heterogeneous syndrome, with phenotypic clustering identifying distinct subgroups including obese-metabolic, aging-fibrotic, atrial fibrillation-related, and pulmonary hypertension-predominant phenotypes.

Diagnosis in Elderly

Clinical Challenges

Diagnosing heart failure in elderly patients presents unique challenges due to atypical presentations and overlapping comorbidities. Rather than presenting with classic dyspnea and edema, elderly patients frequently present with fatigue, confusion, anorexia, and functional decline. Comorbidities commonly mimic HF symptoms: COPD produces dyspnea, obesity causes exercise intolerance, deconditioning limits functional capacity, anemia causes fatigue, and depression produces low energy and withdrawal. Physical examination findings are less reliable in elderly patients: jugular venous pressure assessment is difficult with kyphosis, edema may result from venous insufficiency rather than volume overload, and crackles may represent atelectasis rather than pulmonary congestion. Heart failure in the elderly often presents as a geriatric syndrome, manifesting as falls, delirium, or functional decline rather than through classic cardiovascular symptoms.

Diagnostic Workup

Brain natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP) are cornerstone biomarkers for heart failure diagnosis. NT-proBNP requires age-adjusted cut-offs for diagnosing acute HF: values below 300 pg/mL effectively rule out HF, while thresholds for likely HF are 450 pg/mL for patients under 50, 900 pg/mL for those aged 50 to 75, and 1800 pg/mL for patients over 75. BNP values above 100 pg/mL suggest HF, with values above 400 pg/mL in the acute setting being more definitive. Important confounders include obesity, which reduces BNP levels, and renal dysfunction, which increases them.

Echocardiography is essential for assessing ejection fraction, wall motion abnormalities, valvular disease, diastolic function parameters, and estimated pulmonary artery systolic pressure. An E/e' ratio above 14 suggests elevated filling pressures, and a left atrial volume index above 34 mL/m-squared indicates chronic diastolic dysfunction. Electrocardiography may reveal left ventricular hypertrophy, prior myocardial infarction, atrial fibrillation, or conduction abnormalities. Chest X-ray can show cardiomegaly, pulmonary congestion, and pleural effusions.

Cardiac amyloidosis should be considered in any elderly patient with unexplained HFpEF and left ventricular hypertrophy, especially in men aged 75 and older. Technetium pyrophosphate (Tc-PYP) scanning with grade 2 or 3 uptake is diagnostic of ATTR amyloidosis after ruling out AL amyloidosis with serum and urine immunofixation and free light chain measurements.

<image>A diagnostic workup algorithm for heart failure in elderly patients. Start with "Clinical suspicion of HF (dyspnea, fatigue, edema, OR atypical: confusion, falls, functional decline)." First step: NT-proBNP with age-adjusted cut-offs displayed in a table (age <50: 450; 50-75: 900; >75: 1800 pg/mL). If elevated: proceed to echocardiography. Branch based on EF: HFrEF (≤40%), HFmrEF (41-49%), HFpEF (≥50%). For HFpEF: show additional diagnostic criteria (E/e' >14, LAVI >34, elevated PASP, elevated BNP). Include a "Red flags for cardiac amyloidosis" box: LVH with low voltage on ECG, bilateral CTS history, spinal stenosis, neuropathy, HFpEF with LVH in men ≥75 → Tc-PYP scan pathway. Show common mimics to consider: COPD, obesity-related dyspnea, deconditioning, anemia, pulmonary hypertension. Include the H2FPEF score for diagnosing HFpEF when uncertain (obese, elderly, AF, high E/e', high PASP, elevated BNP).</image>

Management of HFrEF in the Elderly

Guideline-Directed Medical Therapy (GDMT)

The four pillars of guideline-directed medical therapy apply to elderly patients but require careful initiation and monitoring, with attention to the narrower physiological margins that characterize aging.

RAAS Inhibition

ACE inhibitors and ARBs reduce mortality and hospitalization and should be initiated at low doses, such as lisinopril 2.5 to 5 mg or losartan 25 mg, with gradual uptitration. Sacubitril/valsartan (Entresto) demonstrated superiority over enalapril in the PARADIGM-HF trial, achieving a 20 percent reduction in cardiovascular death and HF hospitalization. It should be started at 24/26 mg twice daily and titrated to 97/103 mg twice daily. Elderly-specific monitoring considerations include vigilance for hypotension (particularly when systolic blood pressure is below 100 mmHg), hyperkalemia, and acute kidney injury. Any pre-existing ACE inhibitor must be stopped 36 hours before switching to sacubitril/valsartan to avoid angioedema. The PARAGON-HF trial, which studied sacubitril/valsartan in HFpEF, was overall negative but showed subgroup benefit in patients with ejection fraction below 57 percent and in women.

Beta-Blockers

Carvedilol, metoprolol succinate, and bisoprolol are the three evidence-based beta-blockers for HFrEF, reducing mortality by 30 to 35 percent. In elderly patients, these agents should be started at very low doses: carvedilol 3.125 mg twice daily or metoprolol succinate 12.5 to 25 mg daily. Titration should proceed slowly, at intervals of at least two weeks, with monitoring for symptomatic bradycardia, hypotension, and fatigue. Abrupt discontinuation must be avoided, with gradual tapering employed if dose reduction is necessary.

Mineralocorticoid Receptor Antagonists (MRAs)

Spironolactone at 12.5 to 25 mg daily or eplerenone at 25 to 50 mg daily provides significant mortality reduction. The RALES trial demonstrated a 30 percent mortality reduction in severe HF. In elderly patients, the risk of hyperkalemia is the critical concern, necessitating potassium and creatinine monitoring at one week, one month, and at regular intervals thereafter. MRAs should be avoided if potassium exceeds 5.0 mEq/L or creatinine clearance is below 30 mL/min. Gynecomastia occurs in approximately 10 percent of patients on spironolactone and can be managed by switching to eplerenone.

SGLT2 Inhibitors

Dapagliflozin (Farxiga) demonstrated a 26 percent reduction in cardiovascular death and worsening heart failure in the DAPA-HF trial, regardless of diabetes status. Empagliflozin (Jardiance) showed similar benefits in EMPEROR-Reduced. Both are dosed at 10 mg daily. SGLT2 inhibitors offer particular advantages in elderly patients: they are well-tolerated, require no dose titration, do not cause hypotension, and promote modest weight reduction. Side effects include genital mycotic infections (5 to 7 percent), volume depletion, euglycemic diabetic ketoacidosis (rare), and Fournier gangrene (very rare). Subgroup analyses of the pivotal trials demonstrate consistent effectiveness across the age spectrum, including patients aged 75 and older. SGLT2 inhibitors are also beneficial in HFpEF, as demonstrated by the EMPEROR-Preserved and DELIVER trials.

Additional Therapies

Hydralazine combined with isosorbide dinitrate serves as an alternative for patients intolerant of ACE inhibitors or ARBs and is particularly beneficial in Black patients, as demonstrated in the A-HeFT trial. Ivabradine (Corlanor) is indicated when resting heart rate exceeds 70 bpm despite maximally tolerated beta-blocker therapy and the patient is in sinus rhythm, dosed at 2.5 to 7.5 mg twice daily. Loop diuretics including furosemide, bumetanide, and torsemide are essential for volume management, dosed to achieve euvolemia with careful monitoring of electrolytes and renal function. Digoxin provides symptom relief and reduced hospitalization as demonstrated in the DIG trial, with target levels of 0.5 to 0.8 ng/mL. In elderly patients, the narrow therapeutic window necessitates low dosing of 0.0625 to 0.125 mg daily with attention to renal clearance.

Implantable cardioverter-defibrillators (ICDs) for primary prevention in patients with ejection fraction of 35 percent or below despite GDMT require particularly careful shared decision-making in elderly patients, considering life expectancy, frailty, and goals of care. The DANISH trial demonstrated no mortality benefit of ICD in non-ischemic cardiomyopathy in patients older than 68 years. Cardiac resynchronization therapy (CRT) is indicated when left bundle branch block of 150 ms or wider coexists with ejection fraction of 35 percent or below despite GDMT, and its benefits in improving quality of life and reducing hospitalizations persist in elderly patients.

Management of HFpEF in the Elderly

Specific Therapies

SGLT2 inhibitors represent the first medications demonstrated to benefit HFpEF patients. The EMPEROR-Preserved trial showed that empagliflozin achieved a 21 percent reduction in HF hospitalization, and the DELIVER trial demonstrated an 18 percent reduction with dapagliflozin. Diuretics remain essential for managing congestion and providing symptom relief. Spironolactone, while showing an overall neutral result in the TOPCAT trial, demonstrated benefit in the Americas-enrolled subgroup and is commonly used in clinical practice. Comorbidity management is central to HFpEF treatment and includes hypertension control, atrial fibrillation rate or rhythm control, weight management, diabetes control, sleep apnea treatment, and anemia correction.

Cardiac Amyloidosis (ATTR)

Tafamidis (Vyndamax/Vyndaqel) is a transthyretin stabilizer that demonstrated a 30 percent reduction in all-cause mortality and a 32 percent reduction in cardiovascular hospitalization in the ATTR-ACT trial of patients with ATTR cardiomyopathy. It is dosed as tafamidis meglumine 80 mg daily or tafamidis free acid 61 mg daily. The high cost of approximately 225,000 dollars per year is a significant consideration, and early treatment before the development of advanced heart failure is critical for optimal benefit.

Geriatric-Specific Considerations

Symptom Burden and Quality of Life

Management of heart failure in elderly patients should focus on functional status and quality of life rather than exclusively on ejection fraction and biomarkers. The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a validated patient-reported outcome measure in which a 5-point change is considered clinically meaningful. Many elderly patients prioritize symptom relief and independence over longevity, and treatment goals should be aligned with these preferences.

Polypharmacy and Medication Complexity

Full GDMT for HFrEF requires a minimum of four medications, adding substantially to the existing medication burden in elderly patients with multiple comorbidities. Strategies to address this include simplifying regimens with once-daily formulations and combination pills such as sacubitril/valsartan, and eliminating unnecessary medications through deprescribing. Medications that worsen heart failure, including NSAIDs, certain calcium channel blockers (diltiazem and verapamil are contraindicated in HFrEF, though amlodipine is safe), and thiazolidinediones (which cause fluid retention), should be identified and discontinued.

Hypotension Challenges

Elderly patients have a narrower blood pressure tolerance, and systolic blood pressure below 100 mmHg frequently limits GDMT titration. A pragmatic approach prioritizes SGLT2 inhibitors (which require no titration and have minimal hypotensive effect) and MRAs (which carry low hypotension risk) as medications that can often be added even when ACE inhibitor/ARB and beta-blocker doses are limited by blood pressure. Accepting suboptimal GDMT doses rather than withholding medications entirely is a fundamental principle: some dose of all four pillars is better than full dose of one.

Diuretic Management

Elderly patients are particularly susceptible to volume depletion, electrolyte disturbances, and acute kidney injury from diuretic therapy. Daily weight monitoring with clear instructions to patients and caregivers to report weight gain exceeding 2 pounds in one day or 5 pounds in one week enables early intervention. Flexible diuretic protocols, in which patients self-adjust furosemide dose based on weight and symptoms, have been shown to reduce hospitalizations.

End-of-Life Considerations

ICD deactivation should be discussed as part of advance care planning, as ICD shocks at end of life cause significant distress without improving comfort. Transition to palliative care should be considered when patients have NYHA class III to IV symptoms despite optimal therapy, experience recurrent hospitalizations, or demonstrate declining functional status. Hospice eligibility criteria for heart failure include ejection fraction of 20 percent or below, NYHA class IV symptoms at rest despite optimal therapy, with an estimated prognosis of six months or less.

<image>A medication management diagram for elderly HFrEF patients showing the four pillars of GDMT with geriatric-specific dosing and considerations. Display four vertical pillars, each representing a drug class. Pillar 1: RAAS inhibition — show starting dose ladder (sacubitril/valsartan 24/26 BID → 49/51 → 97/103; or lisinopril 2.5 → 5 → 10 → 20 mg). Pillar 2: Beta-blocker — show starting dose ladder (carvedilol 3.125 BID → 6.25 → 12.5 → 25; or metoprolol XL 12.5 → 25 → 50 → 100 → 200 mg). Pillar 3: MRA — spironolactone 12.5 → 25 mg with potassium monitoring schedule. Pillar 4: SGLT2i — dapagliflozin 10 mg or empagliflozin 10 mg (no titration needed, highlighted as advantage in elderly). Below each pillar, show geriatric-specific cautions in red boxes: hypotension (pillars 1-2), hyperkalemia (pillars 1, 3), AKI (pillar 3), genital infections (pillar 4). At the bottom, show a "Medication Interaction Alert" section listing drugs to AVOID in HF: NSAIDs, diltiazem/verapamol, TZDs, most antiarrhythmics except amiodarone. Include a note: "In elderly: START all four pillars at low doses simultaneously rather than sequential full-dose titration — get all pillars on board early."</image>

Key Clinical Pearls

• HFpEF is the dominant HF phenotype in the elderly — SGLT2 inhibitors (empagliflozin, dapagliflozin) are the first medications proven to benefit these patients
• Always consider cardiac amyloidosis (ATTRwt) in elderly patients with HFpEF and LVH, especially men ≥75 — a Tc-PYP scan is non-invasive and diagnostic; tafamidis reduces mortality by 30%
• SGLT2 inhibitors are the easiest GDMT pillar to add in elderly HFrEF — no dose titration, no hypotension concern, and they work across the EF spectrum
• NT-proBNP cut-offs are age-adjusted — use >1800 pg/mL for patients >75 in the acute setting; lower thresholds will over-diagnose
• Accept suboptimal GDMT doses in elderly rather than withholding medications entirely — some dose of all four pillars is better than full dose of one
• ICD deactivation should be part of every advance care planning conversation in elderly HF patients — ICD shocks at end of life are distressing and do not improve comfort
• HF in the elderly often presents as a geriatric syndrome (confusion, falls, functional decline) rather than classic dyspnea and edema — maintain a high index of suspicion

References

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.
2. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation. 2022;145(18):e895-e1032.
3. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089-1098.
4. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016.
5. Rich MW, Chyun DA, Skolnick AH, et al. Knowledge gaps in cardiovascular care of the older adult population: a scientific statement from the AHA, ACC, and AGS. Circulation. 2016;133(21):2103-2122.

Read this lecture as Markdown